Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease
about
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).Activation of Nrf2 signaling by natural products-can it alleviate diabetes?Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress.Development of bioresources in Okinawa: understanding the multiple targeted actions of antioxidant phytochemicalsNovel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
P2860
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@ast
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@en
type
label
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@ast
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@en
prefLabel
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@ast
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@en
P2093
P2860
P50
P356
P1433
P1476
Discovery of the first dual GS ...... rategy for Alzheimer's disease
@en
P2093
Antonio Cuadrado
Geoffrey Wells
Giammarco Tenti
Isabel Gameiro
Izaskun Buendia
J Carlos Menéndez
Manuela G López
María Teresa Ramos
Nikolaos D Georgakopoulos
Ángel Cores
P2860
P2888
P356
10.1038/SREP45701
P407
P577
2017-03-31T00:00:00Z